Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors

European Journal of Immunology
Mio NukiwaToshiaki Kikuchi

Abstract

Fractalkine (CX3CL1) is a unique membrane-bound CX3C chemokine that serves as a potent chemoattractant for lymphocytes. The hypothesis of this study is that dendritic cells (DC) genetically modified ex vivo to overexpress fractalkine would enhance the T cell-mediated cellular immune response with a consequent induction of anti-tumor immunity to suppress tumor growth. To prove this hypothesis, established tumors of different mouse cancer cells (B16-F10 melanoma, H-2b, and Colon-26 colon adenocarcinoma, H-2d) were treated with intratumoral injection of bone marrow-derived DC that had been modified in vitro with an RGD fiber-mutant adenovirus vector expressing mouse fractalkine (Ad-FKN). In both tumor models tested, treatment of tumor-bearing mice with Ad-FKN-transduced DC gave rise to a significant suppression of tumor growth along with survival advantages in the treated mice. Immunohistochemical analysis of tumors treated with direct injection of Ad-FKN-transduced DC demonstrated that the treatment prompted CD8+ T cells and CD4+ T cells to accumulate in the tumor milieu, leading to activation of immune-relevant processes. Consistent with the finding, the intratumoral administration of Ad-FKN-transduced DC evoked tumor-specific c...Continue Reading

References

Feb 13, 1997·Nature·J F BazanT J Schall
Jun 3, 2000·Annual Review of Immunology·J BanchereauK Palucka
Jun 10, 2000·Immunology and Cell Biology·I D Davis
Mar 29, 2001·Nature Immunology·S A Luther, J G Cyster
Mar 29, 2001·Nature Immunology·M J SmythJ A Trapani
May 9, 2001·The Journal of Clinical Investigation·P FraticelliA Mantovani
Jan 16, 2002·Current Opinion in Immunology·Andrew D Luster
Mar 27, 2002·Nature Reviews. Immunology·Bernhard HomeyAlbert Zlotnik
Sep 13, 2002·Immunology and Cell Biology·Shaun R McColl
Jan 7, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Hidetake MatsuyoshiYasuharu Nishimura
Jan 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Toshiaki KikuchiToshihiro Nukiwa
Mar 23, 2004·Annual Review of Immunology·Sergio A QuezadaRandolph J Noelle
Apr 23, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Seok-Chul YangSherven Sharma
Mar 25, 2005·European Journal of Immunology·Hong XinYasuo Saijo
Apr 2, 2005·Nature Reviews. Immunology·Jacques Banchereau, A Karolina Palucka
Apr 23, 2005·Immunity·Amanda MurphyMichael H Kershaw
Dec 13, 2005·The Tohoku Journal of Experimental Medicine·Toshiaki Kikuchi

❮ Previous
Next ❯

Citations

Sep 25, 2007·Pharmaceutical Research·Jian-Qing GaoShinsaku Nakagawa
Aug 27, 2011·Cancer Gene Therapy·P Richard-FiardoA Schmid-Alliana
Nov 3, 2007·The Journal of Clinical Investigation·Jamal ZainiToshiaki Kikuchi
Nov 26, 2010·Immunotherapy·Meghan E Turnis, Cliona M Rooney
Jul 20, 2010·Immunotherapy·Elzbieta Pajtasz-Piasecka, Marie Indrová
Sep 6, 2012·Immunotherapy·Elham Mohit, Sima Rafati
Apr 23, 2014·The Journal of Investigative Dermatology·Caroline AspordJoel Plumas
Apr 6, 2007·Expert Review of Vaccines·Chiara Dell'Agnola, Arya Biragyn
Jan 9, 2010·Expert Opinion on Therapeutic Targets·Jan G D'HaeseGüralp O Ceyhan
May 30, 2020·International Journal of Molecular Sciences·Jan KorbeckiIrena Baranowska-Bosiacka

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.